Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by NCR.
Page 1: 1 2 3 4 5 6 7
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
---|---|---|---|---|---|
1 | 1 | 236 | 596 1997 COLUMBIA LAW REVIEW 97(7):2153-2176 Bernstein A Formed by thalidomide: Mass torts as a false cure for toxic exposure | 1 | 6 |
2 | 51 | 221 | 964 2000 CLINICS IN DERMATOLOGY 18(1):131-145 Sanchez MR Miscellaneous treatments: Thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine | 0 | 3 |
3 | 156 | 221 | 1706 2003 CLINICAL THERAPEUTICS 25(2):342-395 Matthews SJ; McCoy C Thalidomide: A review of approved and investigational uses | 2 | 6 |
4 | 3 | 219 | 248 1988 TERATOLOGY 38(3):241-251 BRENT RL; HOLMES LB CLINICAL AND BASIC SCIENCE LESSONS FROM THE THALIDOMIDE TRAGEDY - WHAT HAVE WE LEARNED ABOUT THE CAUSES OF LIMB DEFECTS | 7 | 37 |
5 | 64 | 215 | 541 1996 JOURNAL OF INFLAMMATION 46(4):177-211 Zwingenberger K; Wnendt S Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations | 33 | 38 |
6 | 99 | 191 | 1087 2001 BIODRUGS 15(10):681-703 Meierhofer C; Dunzendorfer S; Wiedermann CJ Theoretical basis for the activity of thalidomide | 7 | 14 |
7 | 151 | 187 | 1581 2003 ANNALS OF PHARMACOTHERAPY 37(9):1307-1320 Nasca MR; Micali G; Cheigh NH; West LE; West DP Dermatologic and nondermatologic uses of thalidomide | 1 | 1 |
8 | 26 | 174 | 893 2000 BIOCHEMICAL PHARMACOLOGY 59(12):1489-1499 Stephens TD; Bunde CJW; Fillmore BJ Mechanism of action in thalidomide teratogenesis | 24 | 36 |
9 | 102 | 164 | 1440 2002 DRUGS & AGING 19(2):85-100 Zhou SF; Kestell P; Tingle MD; Paxton JW Thalidomide in cancer treatment - A potential role in the elderly? | 4 | 5 |
10 | 128 | 159 | 1943 2004 LANCET 363(9423):1802-1811 Franks ME; Macpherson GR; Figg WD Thalidomide | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
11 | 92 | 148 | 1028 2000 NATIONAL MEDICAL JOURNAL OF INDIA 13(3):132-141 Grover JK; Vats V; Gopalakrishna R; Ramam M Thalidomide: A re-look | 2 | 3 |
12 | 1 | 144 | 120 1984 JOURNAL OF THEORETICAL BIOLOGY 110(3):461-486 SHULL GE DIFFERENTIAL INHIBITION OF PROTEIN-SYNTHESIS - A POSSIBLE BIOCHEMICAL-MECHANISM OF THALIDOMIDE TERATOGENESIS | 4 | 6 |
13 | 73 | 144 | 1720 2003 EXPERT OPINION ON INVESTIGATIONAL DRUGS 12(7):1211-1225 Fanelli M; Sarmiento R; Gattuso D; Carillio G; Capaccetti B; Vacca A; Roccaro AM; Gasparini G Thalidomide: a new anticancer drug? | 3 | 7 |
14 | 44 | 140 | 1183 2001 DRUG SAFETY 24(2):87-117 Clark TE; Edom N; Larson J; Lindsey LJ Thalomid (R) (Thalidomide) capsules - A review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing | 11 | 14 |
15 | 69 | 136 | 868 1999 TERATOLOGY 60(5):306-321 Miller MT; Stromland K Teratogen update: Thalidomide: A review, with a focus on ocular findings and new potential uses | 7 | 19 |
16 | 75 | 130 | 1423 2002 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 20(5):709-718 Ossandon A; Cassara EAM; Priori R; Valesini G Thalidomide: focus on its employment in rheumatologic diseases | 2 | 4 |
17 | 26 | 123 | 1176 2001 CURRENT OPINION IN ONCOLOGY 13(5):374-381 Krown SE Management of Kaposi sarcoma: the role of interferon and thalidomide | 2 | 17 |
18 | 41 | 120 | 971 2000 DRUGS 60(2):273-292 Peuckmann V; Fisch M; Bruera E Potential novel uses of thalidomide - Focus on palliative care | 27 | 40 |
19 | 80 | 118 | 1415 2002 CANCER INVESTIGATION 20(5-6):835-848 Baidas S; Tfayli A; Bhargava P Thalidomide: An old drug with new clinical applications | 1 | 3 |
20 | 85 | 116 | 881 2000 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 127(6-7):603-613 Laffitte E; Revuz J Thalidomide | 7 | 9 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
21 | 58 | 116 | 1072 2001 ANNALS OF MEDICINE 33(8):516-525 Ginsburg PM; Dassopoulos T; Ehrenpreis ED Thalidomide treatment for refractory Crohn's disease: a review. of the history, pharmacological mechanisms and clinical literature | 9 | 13 |
22 | 92 | 115 | 1177 2001 DERMATOLOGIC CLINICS 19(1):87-+ Radomsky CL; Levine N Thalidomide | 4 | 8 |
23 | 75 | 113 | 894 2000 BIODRUGS 13(4):255-265 Kontogiannis V; Powell RJ Use of thalidomide in dermatological indications | 0 | 0 |
24 | 63 | 112 | 1298 2002 ANNUAL REVIEW OF MEDICINE 53:629-657 Richardson P; Hideshima T; Anderson K Thalidomide: Emerging role in cancer medicine | 23 | 36 |
25 | 21 | 108 | 634 1997 MEDICAL HYPOTHESES 49(2):123-131 McCarty MF Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: Potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis | 17 | 31 |
26 | 58 | 107 | 1433 2002 CROATIAN MEDICAL JOURNAL 43(3):274-285 Mujagic H; Chabner BA; Mujagic Z Mechanisms of action and potential therapeutic uses of thalidomide | 1 | 2 |
27 | 41 | 106 | 267 1990 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 117(4):313-321 REVUZ J THALIDOMIDE | 16 | 21 |
28 | 69 | 104 | 1826 2003 SWISS MEDICAL WEEKLY 133(5-6):77-87 von Moos R; Stolz R; Cerny T; Gillessen S Thalidomide: from tragedy to promise | 1 | 1 |
29 | 74 | 101 | 546 1996 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 35(6):969-979 Tseng S; Pak G; Washenik K; Pomeranz MK; Shupack JL Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses | 78 | 117 |
30 | 20 | 98 | 954 2000 CANCER TREATMENT REVIEWS 26(5):351-362 Rajkumar SV; Witzig TE A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma | 29 | 53 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
31 | 62 | 96 | 877 2000 AMERICAN JOURNAL OF MEDICINE 108(6):487-495 Calabrese L; Fleischer AB Thalidomide: Current and potential clinical applications | 60 | 103 |
32 | 51 | 96 | 1049 2000 SEMINARS IN HEMATOLOGY 37(1):5-14 Stirling DI Pharmacology of thalidomide | 21 | 23 |
33 | 45 | 95 | 965 2000 CURRENT OPINION IN ONCOLOGY 12(6):564-573 Thomas DA; Kantarjian HM Current role of thalidomide in cancer treatment | 16 | 41 |
34 | 35 | 95 | 1817 2003 SCHMERZ 17(3):204-+ Peuckmann V; Strumpf M; Zenz M; Bruera E Novel potential uses of thalidomide in the management of pain? A review of the literature | 0 | 0 |
35 | 51 | 94 | 1747 2003 JOURNAL OF CLINICAL ONCOLOGY 21(23):4444-4454 Dimopoulos MA; Anagnostopoulos A; Weber D Treatment of plasma cell dyserasias with thalidomide and its derivatives | 1 | 2 |
36 | 50 | 93 | 1311 2002 BIOMEDICINE & PHARMACOTHERAPY 56(3):115-128 Richardson P; Hideshima T; Anderson K Thalidomide in multiple myeloma | 5 | 6 |
37 | 26 | 91 | 1313 2002 BIOORGANIC & MEDICINAL CHEMISTRY 10(3):461-479 Hashimoto Y Structural development of biological response modifiers based on thalidomide | 8 | 15 |
38 | 19 | 91 | 1845 2004 ANTIOXIDANTS & REDOX SIGNALING 6(1):1-14 Hansen JM; Harris C A novel hypothesis for thalidomide-induced limb teratogenesis: Redox misregulation of the NF-kappa B pathway | 0 | 0 |
39 | 31 | 89 | 351 1993 ARCHIVES OF TOXICOLOGY 67(1):1-17 NEUBERT R; NOGUEIRA AC; NEUBERT D THALIDOMIDE DERIVATIVES AND THE IMMUNE-SYSTEM .1. CHANGES IN THE PATTERN OF INTEGRIN RECEPTORS AND OTHER SURFACE-MARKERS ON LYMPHOCYTE-T SUBPOPULATIONS OF MARMOSET BLOOD | 40 | 49 |
40 | 66 | 87 | 742 1998 SEMINARS IN CUTANEOUS MEDICINE AND SURGERY 17(4):231-242 Stirling DI Thalidomide and its impact in dermatology | 14 | 17 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
41 | 59 | 87 | 1188 2001 EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY 57(5):365-376 Eriksson T; Bjorkman S; Hoglund P Clinical pharmacology of thalidomide | 22 | 32 |
42 | 49 | 86 | 1707 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S49-S57 Macpherson GR; Franks M; Tomoaia-Cotisel A; Ando Y; Price DK; Figg WD Current status of thalidomide and its role in the treatment of metastatic prostate cancer | 1 | 2 |
43 | 20 | 85 | 379 1994 ADVERSE DRUG REACTIONS AND TOXICOLOGICAL REVIEWS 13(4):177-192 CRAWFORD CL USE OF THALIDOMIDE IN LEPROSY | 8 | 11 |
44 | 0 | 83 | 1552 2002 SOCIAL HISTORY OF MEDICINE 15(1):137-158 Daemmrich A A tale of two experts: Thalidomide and political engagement in the United States and West Germany | 0 | 0 |
45 | 50 | 83 | 1957 2004 MAYO CLINIC PROCEEDINGS 79(7):899-903 Rajkumar SV Thalidomide: Tragic past and promising future | 0 | 0 |
46 | 15 | 82 | 1309 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):20-30 Zorat F; Pozzato G Thalidomide in myelodysplastic syndromes | 3 | 3 |
47 | 57 | 82 | 1432 2002 CRITICAL REVIEWS IN IMMUNOLOGY 22(5-6):425-437 Dredge K; Marriott JB; Dalgleish AG Immunological effects of thalidomide and its chemical and functional analogs | 0 | 2 |
48 | 70 | 82 | 1843 2004 ANNALS OF ONCOLOGY 15(8):1151-1160 Eleutherakis-Papaiakovou V; Bamias A; Dimopoulos MA Thalidomide in cancer medicine | 0 | 0 |
49 | 22 | 80 | 694 1998 CURRENT MEDICINAL CHEMISTRY 5(3):163-178 Hashimoto Y Novel biological response modifiers derived from thalidomide | 16 | 38 |
50 | 29 | 79 | 751 1999 ANNALS OF THE RHEUMATIC DISEASES 58:107-113 Corral LG; Kaplan G Immunomodulation by thalidomide and thalidomide analogues | 13 | 18 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
51 | 48 | 79 | 761 1999 BIODRUGS 11(6):409-416 Powell RJ Thalidomide - Current uses | 1 | 2 |
52 | 23 | 79 | 845 1999 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 425(1):153-167 Zhu XY; Zhang YP; Klopman G; Rosenkranz HS Thalidomide and metabolites: indications of the absence of 'genotoxic' carcinogenic potentials | 3 | 3 |
53 | 41 | 78 | 1812 2003 PHARMACOTHERAPY 23(4):481-493 Okafor MC Thalidomide for erythema nodosum leprosum and other applications | 0 | 0 |
54 | 40 | 78 | 1901 2004 EXPERT OPINION ON THERAPEUTIC PATENTS 14(2):215-229 Luzzio FA; Figg WD Thalidomide analogues: derivatives of an orphan drug with diverse biological activity | 0 | 0 |
55 | 66 | 77 | 1814 2003 POSTGRADUATE MEDICAL JOURNAL 79(929):127-132 Gordon JN; Goggin PM Thalidomide and its derivatives: emerging from the wilderness | 0 | 3 |
56 | 5 | 76 | 544 1996 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 277(3):1649-1658 Arlen RR; Wells PG Inhibition of thalidomide teratogenicity by acetylsalicylic acid: Evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate | 9 | 15 |
57 | 48 | 74 | 607 1997 INTERNATIONAL JOURNAL OF DERMATOLOGY 36(12):881-887 Calderon P; Anzilotti M; Phelps R Thalidomide in dermatology. New indications for an old drug | 22 | 27 |
58 | 50 | 73 | 1086 2001 BIODRUGS 15(3):163-172 Singhal S; Mehta J Thalidomide in cancer - Potential uses and limitations | 12 | 16 |
59 | 30 | 71 | 1305 2002 BIOLOGICAL & PHARMACEUTICAL BULLETIN 25(5):597-604 Marks MG; Shi JD; Fry MO; Xiao ZL; Trzyna M; Pokala V; Ihnat MA; Li PK Effects of putative hydroxylated thalidomide metabolites on blood vessel density in the chorioallantoic membrane (CAM) assay and on tumor and endothelial cell proliferation | 6 | 9 |
60 | 12 | 70 | 800 1999 DRUGS 58(6):953-963 Ravot E; Lisziewicz J; Lori F New uses for old drugs in HIV infection - The role of hydroxyurea, cyclosporin and thalidomide | 3 | 15 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
61 | 28 | 70 | 1254 2001 ONCOLOGY-NEW YORK 15(7):867-874 Rajkumar SV Current status of thalidomide in the treatment of cancer | 9 | 14 |
62 | 57 | 70 | 1739 2003 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 785(1):165-173 Zhou SF; Lia Y; Kestell P; Paxton JW Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection | 0 | 0 |
63 | 0 | 68 | 1054 2000 SOCIAL STUDIES OF SCIENCE 30(1):41-71 Timmermans S; Leiter V The redemption of thalidomide: Standardizing the risk of birth defects | 0 | 1 |
64 | 48 | 68 | 1208 2001 HAUTARZT 52(8):726-733 Kuhn A; Hefter H; Ruzicka T; Lehmann P Rediscovery of thalidomide. Successful treatment of discoid lupus erythematosus | 0 | 0 |
65 | 13 | 67 | 1004 2000 JOURNAL OF CLINICAL ONCOLOGY 18(13):2593-2602 Little RF; Wyvill KM; Pluda JM; Welles L; Marshall V; Figg WD; Newcomb FM; Tosato G; Feigal E; Steinberg SM; Whitby D; Goedert JJ; Yarchoan R Activity of thalidomide in AIDS-related Kaposis's sarcoma | 45 | 83 |
66 | 31 | 67 | 1160 2001 CANCER 92(9):2364-2373 Tseng JE; Glisson BS; Khuri FR; Shin DM; Myers JN; El-Naggar AK; Roach JS; Ginsberg LE; Thall PF; Wang XM; Teddy S; Lawhorn KN; Zentgraf RE; Steinhaus GD; Pluda JM; Abbruzzese JL; Hong WK; Herbst RS Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck | 7 | 14 |
67 | 44 | 67 | 1184 2001 DRUGS 61(6):777-787 Bousvaros A; Mueller B Thalidomide in gastrointestinal disorders | 4 | 8 |
68 | 39 | 67 | 1479 2002 JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 6(2):160-174 Kumar S; Witzig TE; Rajkumar SV Thalidomide as an anti-cancer agent | 6 | 10 |
69 | 37 | 67 | 1494 2002 JOURNAL OF IMMUNOLOGY 168(6):2644-2651 Majumdar S; Lamothe B; Aggarwal BB Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester | 12 | 25 |
70 | 44 | 67 | 1806 2003 ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 95(5):576-585 Hegarty A; Hodgson T; Porter S Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis | 1 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
71 | 2 | 66 | 85 1983 HAUTARZT 34(2):66-72 HUNZIKER T; KREBS A THALIDOMIDE IN DERMATOLOGY | 7 | 7 |
72 | 13 | 66 | 727 1998 MEDICAL HYPOTHESES 50(4):313-318 Argiles JM; Carbo N; Lopez-Soriano FJ Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s? | 11 | 12 |
73 | 3 | 65 | 510 1996 BIOGENIC AMINES 12(4):305-326 Audit CO Specific functions of polyamines: Actin assembly, cytokinesis induction, targets for thalidomide activity, nitrogen sources for marine ecosystems | 1 | 3 |
74 | 43 | 65 | 1563 2003 AMERICAN JOURNAL OF CLINICAL DERMATOLOGY 4(6):379-387 Pelle MT; Werth VP Thalidomide in cutaneous lupus erythematosus | 0 | 0 |
75 | 42 | 65 | 1890 2004 CLINICAL PHARMACOKINETICS 43(5):311-327 Teo SK; Colburn WA; Tracewell WG; Kook KA; Stirling DI; Jaworsky MS; Scheffler MA; Thomas SD; Laskin OL Clinical pharmacokinetics of thalidomide | 1 | 1 |
76 | 21 | 64 | 263 1989 MEDICAL HYPOTHESES 30(2):105-109 GUNZLER V THALIDOMIDE - A THERAPY FOR THE IMMUNOLOGICAL CONSEQUENCES OF HIV INFECTION | 4 | 6 |
77 | 14 | 63 | 1181 2001 DRUG DEVELOPMENT RESEARCH 54(4):209-218 Fernandez-Martinez E; Morales-Rios MS; Perez-Alvarez V; Muriel P Effects of thalidomide and 3-phthalimido-3-(3,4-dimethoxyphenyl)-propanamide on bile duct obstruction-induced cirrhosis in the rat | 2 | 3 |
78 | 11 | 63 | 1830 2004 ACTA NEUROBIOLOGIAE EXPERIMENTALIS 64(1):1-9 Greig NH; Giordano T; Zhu XX; Yu QS; Perry TA; Holloway HW; Brossi A; Rogers JT; Sambamurti K; Lahiri DK Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases | 0 | 0 |
79 | 22 | 61 | 117 1984 INTERNATIONAL JOURNAL OF DERMATOLOGY 23(9):598-602 GROSSHANS E; ILLY G THALIDOMIDE THERAPY FOR INFLAMMATORY DERMATOSES | 55 | 62 |
80 | 7 | 61 | 247 1988 TERATOLOGY 38(3):229-239 STEPHENS TD PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 40 | 64 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
81 | 25 | 61 | 378 1994 ADVERSE DRUG REACTIONS AND TOXICOLOGICAL REVIEWS 13(2):65-76 DARCY PF; GRIFFIN JP THALIDOMIDE REVISITED | 22 | 27 |
82 | 53 | 61 | 1307 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):4-12 Singhal S; Mehta J Thalidomide in cancer | 17 | 21 |
83 | 53 | 61 | 1541 2002 ORAL ONCOLOGY 38(6):527-531 Porter SR; Jorge J Thalidomide: a role in oral oncology? | 0 | 1 |
84 | 29 | 60 | 697 1998 EXPERIMENTAL HEMATOLOGY 26(3):217-221 Or R; Feferman R; Shoshan S Thalidomide reduces vascular density in granulation tissue of subcutaneously implanted polyvinyl alcohol sponges in guinea pigs | 18 | 24 |
85 | 9 | 60 | 878 2000 AMERICAN JOURNAL OF NEURORADIOLOGY 21(5):881-890 Cha S; Knopp EA; Johnson G; Litt A; Glass J; Gruber ML; Lu S; Zagzag D Dynamic contrast-enhanced T2*-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin | 3 | 24 |
86 | 36 | 60 | 1164 2001 CELLULAR AND MOLECULAR BIOLOGY 47(7):1105-1114 Settles B; Stevenson A; Wilson K; Mack C; Ezell T; Davis MF; Taylor LD Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide | 7 | 10 |
87 | 10 | 60 | 1833 2004 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 19(1):79-88 Austin AS; Mahida YR; Clarke D; Ryder SD; Freeman JG A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis | 0 | 0 |
88 | 1 | 59 | 222 1988 ARCHIVES OF TOXICOLOGY 61(3):165-179 MERKER HJ; HEGER W; SAMES K; STURJE H; NEUBERT D EMBRYOTOXIC EFFECTS OF THALIDOMIDE-DERIVATIVES IN THE NON-HUMAN PRIMATE CALLITHRIX-JACCHUS .1. EFFECTS OF 3-(1,3-DIHYDRO-1-OXO-2H-ISOINDOL-2-YL)-2,6-DIOXOPIPERIDINE (EM-12) ON SKELETAL DEVELOPMENT | 10 | 18 |
89 | 8 | 59 | 635 1997 MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS 396(1-2):45-64 Ashby J; Tinwell H; Callander RD; Kimber I; Clay P; Galloway SM; Hill RB; Greenwood SK; Gaulden ME; Ferguson MJ; Vogel E; Nivard M; Parry JM; Williamson J Thalidomide: lack of mutagenic activity across phyla and genetic endpoints | 12 | 14 |
90 | 16 | 59 | 1047 2000 QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS 93(5):305-311 Davey PP; Ashrafian H New therapies for heart failure: is thalidomide the answer? | 6 | 9 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
91 | 12 | 59 | 1095 2001 BLOOD 98(4):958-965 Raza A; Meyer P; Dutt D; Zorat F; Lisak L; Nascimben F; du Randt M; Kaspar C; Goldberg C; Loew J; Dar S; Gezer S; Venugopal P; Zeldis J Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes | 29 | 64 |
92 | 30 | 59 | 1390 2002 BLOOD REVIEWS 16(4):207-215 Strasser K; Ludwig H Thalidomide treatment in multiple myeloma | 3 | 4 |
93 | 40 | 59 | 1709 2003 CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT 6(1):92-99 Meierhofer C; Wiedermann CJ New insights into the pharmacological and toxicological effects of thalidomide | 3 | 3 |
94 | 15 | 59 | 1951 2004 LEUKEMIA RESEARCH 28(4):325-332 Musto P Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives | 0 | 0 |
95 | 12 | 57 | 1038 2000 ONCOLOGY-NEW YORK 14(12):11-16 Rajkumar SV Thalidomide in multiple myeloma | 9 | 17 |
96 | 13 | 57 | 1787 2003 LEUKEMIA & LYMPHOMA 44(2):291-298 Ribas C; Colleoni GWB Advances in the treatment of multiple myeloma: The role of thalidomide | 0 | 1 |
97 | 39 | 57 | 1965 2004 NATURE REVIEWS CANCER 4(4):314-322 Bartlett JB; Dredge K; Dalgleish AG Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents | 2 | 2 |
98 | 12 | 56 | 1173 2001 CLINICAL CANCER RESEARCH 7(11):3349-3355 Fujita J; Mestre JR; Zeldis JB; Subbaramaiah K; Dannenberg AJ Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2 | 22 | 32 |
99 | 29 | 56 | 1973 2004 TOXICOLOGICAL SCIENCES 81(2):379-389 Teo SK; Denny KH; Stirling DI; Thomas SD; Morseth S; Hoberman AM Effects of thalidomide on developmental, peri-and postnatal function in female New Zealand white rabbits and offspring | 0 | 0 |
100 | 10 | 55 | 737 1998 PAIN 74(1):83-91 Sommer C; Marziniak M; Myers RR The effect of thalidomide treatment on vascular pathology and hyperalgesia caused by chronic constriction injury of rat nerve | 5 | 55 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
101 | 23 | 55 | 1257 2001 OPHTHALMIC RESEARCH 33(5):256-263 Baatz H; Tonessen B; Prada J; Pleyer U Thalidomide inhibits leukocyte-endothelium interaction in endotoxin-induced uveitis | 1 | 4 |
102 | 2 | 54 | 48 1982 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 7(3):317-323 BARNHILL RL; MCDOUGALL AC THALIDOMIDE - USE AND POSSIBLE MODE OF ACTION IN REACTIONAL LEPROMATOUS LEPROSY AND IN VARIOUS OTHER CONDITIONS | 84 | 111 |
103 | 25 | 54 | 1425 2002 CLINICAL CANCER RESEARCH 8(6):1964-1973 Ando Y; Fuse E; Figg WD Thalidomide metabolism by the CYP2C subfamily | 14 | 15 |
104 | 27 | 54 | 1946 2004 LEUKEMIA 18(4):856-863 Garcia-Sanz R; Gonzalez-Porras JR; Hernandez JM; Polo-Zarzuela M; Sureda A; Barrenetxea C; Palomera L; Lopez R; Grande-Garcia C; Alegre A; Vargas-Pabon M; Gutierrez ON; Rodriguez JA; San Miguel JF The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma | 0 | 1 |
105 | 30 | 53 | 753 1999 ARCHIVES OF DERMATOLOGY 135(9):1079-1087 Duong DJ; Spigel GT; Moxley RT; Gaspari AA American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus | 20 | 29 |
106 | 8 | 53 | 1158 2001 BRITISH JOURNAL OF HAEMATOLOGY 115(4):881-894 Zorat F; Shetty V; Dutt D; Lisak L; Nascimben F; Allampallam K; Dar S; York A; Gezer S; Venugopal P; Raza A The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes | 14 | 23 |
107 | 40 | 53 | 1189 2001 EXPERT OPINION ON BIOLOGICAL THERAPY 1(4):675-682 Marriott JB; Muller G; Stirling D; Dalgleish AG Immunotherapeutic and antitumour potential of thalidomide analogues | 12 | 16 |
108 | 27 | 53 | 1219 2001 JOURNAL OF BIOLOGICAL CHEMISTRY 276(25):22382-22387 Keifer JA; Guttridge DC; Ashburner BP; Baldwin AS Inhibition of NF-kappa B activity by thalidomide through suppression of I kappa B kinase activity | 33 | 57 |
109 | 33 | 53 | 1434 2002 CURRENT OPINION IN ONCOLOGY 14(6):635-640 Raje N; Anderson KC Thalidomide and immunomodulatory drugs as cancer therapy | 8 | 14 |
110 | 20 | 52 | 456 1995 EXPERIMENTAL HEMATOLOGY 23(9):978-985 FERNANDEZ LP; SCHLEGEL PG; BAKER J; CHEN YF; CHAO NJ DOES THALIDOMIDE AFFECT IL-2 RESPONSE AND PRODUCTION | 21 | 21 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
111 | 38 | 52 | 813 1999 IMMUNOLOGY TODAY 20(12):538-540 Marriott JB; Muller G; Dalgleish AG Thalidomide as an emerging immunotherapeutic agent | 38 | 47 |
112 | 4 | 52 | 823 1999 JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME 81B(1):9-23 McCredie J; Willert HG Longitudinal limb deficiencies and the sclerotomes - An analysis of 378 dysmelic malformations induced by thalidomide | 0 | 8 |
113 | 25 | 52 | 830 1999 JOURNAL OF INVESTIGATIVE DERMATOLOGY 113(5):720-724 Nasca MR; O'Toole EA; Palicharla P; West DP; Woodley DT Thalidomide increases human keratinocyte migration and proliferation | 6 | 15 |
114 | 23 | 52 | 1278 2001 TOXICOLOGICAL SCIENCES 59(1):160-168 Teo SK; Evans MG; Brockman MJ; Ehrhart J; Morgan JM; Stirling DI; Thomas SD Safety profile of thalidomide after 53 weeks of oral administration in beagle dogs | 5 | 5 |
115 | 11 | 52 | 1765 2003 JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION 10(3):252-259 Weeber M; Vos R; Klein H; de Jong-van den Berg LTW; Aronson AR; Molema G Generating hypotheses by discovering implicit associations in the literature: A case report of a search for new potential therapeutic uses for thalidomide. | 0 | 4 |
116 | 24 | 52 | 1895 2004 DRUGS OF TODAY 40(3):197-204 Joglekar S; Levin M The promise of thalidomide: Evolving indications | 0 | 0 |
117 | 5 | 51 | 561 1996 TERATOLOGY 54(3):126-134 Smith DM; Torres RD; Stephens TD Mesonephros has a role in limb development and is related to thalidomide embryopathy | 0 | 6 |
118 | 9 | 51 | 788 1999 CELLULAR AND MOLECULAR BIOLOGY 45(5):579-588 Gaffield W; Incardona JP; Kapur RP; Roelink H A looking glass perspective: Thalidomide and cyclopamine | 0 | 6 |
119 | 40 | 51 | 997 2000 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 6(1):19-26 Lenardo TM; Calabrese LH The role of thalidomide in the treatment of rheumatic disease | 4 | 4 |
120 | 10 | 51 | 1163 2001 CANCER LETTERS 163(2):191-200 Myoung H; Hong SD; Kim YY; Hong SP; Kim MJ Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma | 4 | 10 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
121 | 19 | 51 | 1416 2002 CANCER INVESTIGATION 20(7-8):1051-1058 Jaslow R; Kaplan G; Lyons L; Michaeli J; Coleman M Thalidomide in multiple myeloma-from the clinic to the laboratory | 0 | 0 |
122 | 28 | 50 | 589 1997 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 110(2):151-154 McHugh SM; Rowland TL Thalidomide and derivatives: immunological investigations of tumour necrosis factor-alpha (TNF-alpha) inhibition suggest drugs capable of selective gene regulation | 17 | 32 |
123 | 19 | 50 | 1676 2003 BRITISH JOURNAL OF HAEMATOLOGY 120(1):18-26 Cavenagh JD; Oakervee H; UK Myeloma Forum; BSCH Haematology Oncology Task For Thalidomide in multiple myeloma: Current status and future prospects | 15 | 18 |
124 | 13 | 49 | 958 2000 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 121(3):472-479 Guckian M; Dransfield I; Hay P; Dalgleish AG Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro | 4 | 6 |
125 | 13 | 49 | 960 2000 CLINICAL IMMUNOLOGY 97(2):109-120 Oliver SJ; Moreira A; Kaplan G Immune stimulation in scleroderma patients treated with thalidomide | 11 | 15 |
126 | 30 | 49 | 1178 2001 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 126(42):1178-1182 Tuinmann G; Hegewisch-Becker S; Hossfeld DK New indications for thalidomide | 2 | 3 |
127 | 12 | 49 | 1429 2002 CLINICAL IMMUNOLOGY 102(3):225-236 Oliver SJ; Kikuchi T; Krueger JG; Kaplan G Thalidomide induces granuloma differentiation in sarcoid skin lesions associated with disease improvement | 4 | 8 |
128 | 10 | 48 | 827 1999 JOURNAL OF IMMUNOLOGY 163(1):380-386 Corral LG; Haslett PAJ; Muller GW; Chen R; Wong LM; Ocampo CJ; Patterson RT; Stirling DI; Kaplan G Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha | 80 | 127 |
129 | 20 | 48 | 1263 2001 QUIMICA NOVA 24(5):683-688 Lima LM; Fraga CAM; Barreiro EJ The rebirth of a drug: Thalidomide | 0 | 1 |
130 | 6 | 48 | 1268 2001 SEMINARS IN HEMATOLOGY 38(3):250-259 Barlogie B; Zangari M; Spencer T; Fassas A; Anaissie E; Badros A; Cromer J; Tricot G Thalidomide in the management of multiple myeloma | 18 | 31 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
131 | 17 | 48 | 1310 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):31-35 Shek LPC; Lim DLC Thalidomide in Behcet's disease | 7 | 11 |
132 | 10 | 48 | 1816 2003 RHEUMATIC DISEASE CLINICS OF NORTH AMERICA 29(3):481-+ Davis JC; Huang F; Maksymowych W New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate | 0 | 0 |
133 | 16 | 47 | 1185 2001 DRUGS OF THE FUTURE 26(1):100-103 [Anon] Thalidomide - Synovir (R) - Thalomid (R) - Talizer (R) - Oncolytic treatment of IBD antiarthritic treatment of leprosy | 0 | 0 |
134 | 19 | 47 | 1274 2001 SEMINARS IN ONCOLOGY 28(6):597-601 D'Amato RJ; Lentzsch S; Anderson KC; Rogers MS Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma | 0 | 10 |
135 | 11 | 47 | 1546 2002 PHARMACOTHERAPY 22(8):1019-1028 Cool RM; Herrington JD Thalidomide for the treatment of relapsed and refractory multiple myeloma | 1 | 1 |
136 | 15 | 47 | 1602 2003 BLOOD 101(7):2534-2541 Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder GE; Reeder T; Zeldis JB; Tefferi A A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia | 6 | 10 |
137 | 25 | 47 | 1847 2004 ARCHIVES OF DERMATOLOGY 140(7):845-849 Maurer T; Poncelet A; Berger T Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects - Efficacy and risk of neuropathy | 0 | 0 |
138 | 17 | 47 | 1850 2004 BIOCHEMICAL PHARMACOLOGY 68(7):1321-1329 Fernandez-Martinez E; Morales-Rios MS; Perez-Alvarez V; Muriel P Immunomodulatory effects of thalidomide analogs on LPS-induced plasma and hepatic cytokines in the rat | 0 | 0 |
139 | 24 | 47 | 1857 2004 BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY 71(1):1-16 Teo SK; Denny KH; Stirling DI; Thomas SD; Morseth SL; Hoberman AM Effects of thalidomide on reproductive function and early embryonic development in male and female New Zealand white rabbits | 1 | 1 |
140 | 0 | 46 | 223 1988 ARCHIVES OF TOXICOLOGY 61(3):180-191 NEUBERT D; HEGER W; MERKER HJ; SAMES K; MEISTER R EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES IN THE NON-HUMAN PRIMATE CALLITHRIX-JACCHUS .2. ELUCIDATION OF THE SUSCEPTIBLE PERIOD AND OF THE VARIABILITY OF EMBRYONIC STAGES | 8 | 21 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
141 | 7 | 46 | 1186 2001 ELECTROPHORESIS 22(15):3185-3190 Schoetz G; Trapp O; Schurig V Determination of the enantiomerization barrier of thalidomide by dynamic capillary electrokinetic chromatography | 1 | 4 |
142 | 19 | 46 | 1752 2003 JOURNAL OF INVESTIGATIVE DERMATOLOGY 121(5):1060-1065 Deng L; Ding WH; Granstein RD Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells | 1 | 1 |
143 | 7 | 45 | 417 1994 LIFE SCIENCES 56(6):407-420 NEUBERT R; HELGE H; NEUBERT D THALIDOMIDE AND THE IMMUNE-SYSTEM .4. DOWN-REGULATION OF THE CD26 RECEPTOR, PROBABLY INVOLVED IN THE BINDING OF HIV COMPONENTS TO T-CELLS IN PRIMATES | 3 | 4 |
144 | 16 | 45 | 426 1994 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 40(5):535-542 ARALACHAVES M; VILANOVA M; RIBEIRO A; PINTO J IMMUNOSTIMULATORY EFFECT OF THALIDOMIDE IN NORMAL C57BL/6 MICE IS COMPATIBLE WITH STIMULATION OF A HIGHLY CONNECTED CENTRAL IMMUNE-SYSTEM .1. | 4 | 6 |
145 | 23 | 45 | 952 2000 CANCER CHEMOTHERAPY AND PHARMACOLOGY 46(2):135-141 Kestell P; Zhao LL; Baguley BC; Palmer BD; Muller G; Paxton JW; Ching LM Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide | 6 | 21 |
146 | 30 | 45 | 1312 2002 BIOMEDICINE & PHARMACOTHERAPY 56(4):194-199 Ng SSW; Brown M; Figg WD Thalidomide, an antiangiogenic agent with clinical activity in cancer | 5 | 6 |
147 | 15 | 45 | 1755 2003 JOURNAL OF MEDICINAL CHEMISTRY 46(24):5222-5229 Zhu XX; Giordano T; Yu QS; Holloway HW; Perry TA; Lahiri DK; Brossi A; Greig NH Thiothalidomides: Novel isosteric analogues of thalidomide with enhanced TNF-alpha inhibitory activity | 2 | 2 |
148 | 25 | 45 | 1935 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 50(2):235-241 Nguyen YT; Dupuy A; Cordoliani F; Vignon-Pennamen MD; Lebbe C; Morel P; Rybojad M Treatment of cutaneous sarcoidosis with thalidomide | 0 | 0 |
149 | 21 | 45 | 1964 2004 MOLECULES AND CELLS 17(2):210-216 Kim YS; Kim JS; Jung HC; Song IS The effects of thalidomide on the stimulation of NF-kappa B activity and TNF-alpha production by lipopolysaccharide in a human colonic epithelial cell line | 0 | 0 |
150 | 14 | 44 | 469 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 32(5):866-869 CARLESIMO M; GIUSTINI S; ROSSI A; BONACCORSI P; CALVIERI S TREATMENT OF CUTANEOUS AND PULMONARY SARCOIDOSIS WITH THALIDOMIDE | 48 | 84 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
151 | 3 | 44 | 573 1997 AMERICAN JOURNAL OF MEDICAL GENETICS 73(3):251-258 Yang QH; Khoury MJ; James LM; Olney RS; Paulozzi LJ; Erickson JD The return of thalidomide: Are birth defects surveillance systems ready? | 1 | 6 |
152 | 21 | 44 | 644 1997 NEW ENGLAND JOURNAL OF MEDICINE 336(21):1487-1493 Jacobson JM; Greenspan JS; Spritzler J; Ketter N; Fahey JL; Jackson JB; Fox L; Chernoff M; Wu AW; MacPhail LA; Vasquez GJ; Wohl DA Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection | 119 | 192 |
153 | 3 | 44 | 797 1999 CURRENT EYE RESEARCH 19(6):483-490 Spraul CW; Kaven C; Kampmeier J; Lang GK; Lang GE Effect of thalidomide, octreotide, and prednisolone on the migration and proliferation of RPE cells in vitro | 5 | 9 |
154 | 12 | 44 | 1007 2000 JOURNAL OF INFECTIOUS DISEASES 181(3):954-965 Bekker LG; Haslett P; Maartens G; Steyn L; Kaplan G Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis | 18 | 27 |
155 | 32 | 44 | 1068 2001 AMERICAN JOURNAL OF THE MEDICAL SCIENCES 321(5):321-326 Moraes M; Russo G Thalidomide and its dermatologic uses | 3 | 9 |
156 | 37 | 44 | 1218 2001 JOINT BONE SPINE 68(6):582-587 Combe B Thalidomide: new indications? | 1 | 3 |
157 | 27 | 44 | 1472 2002 INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 83(2):99-104 Arrieta O; Guevara P; Tamariz J; Rembao D; Rivera E; Sotelo J Antiproliferative effect of thalidomide alone and combined with carmustine against C6 rat glioma | 1 | 3 |
158 | 13 | 44 | 1805 2003 ONCOLOGY 65(3):242-249 Hsu C; Chen CN; Chen LT; Wu CY; Yang PM; Lai MY; Lee PH; Cheng AL Low-dose thalidomide treatment for advanced hepatocellular carcinoma | 2 | 5 |
159 | 10 | 44 | 1846 2004 ARCHIVES OF DERMATOLOGY 140(3):277-280 Caradona S; Jacobe H Thalidomide as a potential treatment for scleromyxedema | 0 | 0 |
160 | 15 | 44 | 1954 2004 MAYO CLINIC PROCEEDINGS 79(7):857-858 Silver RT Myelofibrosis: Thalidomide finds a new disease | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
161 | 15 | 43 | 422 1994 POSTGRADUATE MEDICAL JOURNAL 70(830):860-862 GARDNERMEDWIN JM; POWELL RJ THALIDOMIDE - THE WAY FORWARD | 7 | 10 |
162 | 10 | 43 | 533 1996 INFLAMMATION 20(2):203-215 Kroger H; Miesel R; Dietrich A; Ohde M; Rajnavolgyi E; Ockenfels H Synergistic effects of thalidomide and poly(ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice | 1 | 12 |
163 | 12 | 43 | 567 1997 AIDS RESEARCH AND HUMAN RETROVIRUSES 13(10):857-863 Moreira AL; Corral LG; Ye WG; Johnson B; Stirling D; Muller GW; Freedman VH; Kaplan G Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro | 36 | 47 |
164 | 6 | 43 | 1412 2002 CANCER 95(8):1629-1636 Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma | 8 | 15 |
165 | 11 | 43 | 1853 2004 BIOORGANIC & MEDICINAL CHEMISTRY 12(2):327-336 Capitosti SM; Hansen TP; Brown ML Thalidomide analogues demonstrate dual inhibition of both angiogenesis and prostate cancer | 0 | 2 |
166 | 0 | 42 | 118 1984 JOURNAL OF ANATOMY 139(OCT):397-410 MCCREDIE J; NORTH K; DEIONGH R THALIDOMIDE DEFORMITIES AND THEIR NERVE SUPPLY | 3 | 7 |
167 | 0 | 42 | 147 1985 EUROPEAN JOURNAL OF PHARMACOLOGY 119(1-2):39-46 YOUDIM MBH; ASHKENAZI R SEROTONERGIC INVOLVEMENT IN PHARMACOLOGICAL ACTION OF THE ANXIOLYTIC-SEDATIVES THALIDOMIDE AND SUPIDIMIDE | 0 | 1 |
168 | 23 | 42 | 388 1994 BONE MARROW TRANSPLANTATION 14(6):937-942 COLE CH; ROGERS PCJ; PRITCHARD S; PHILLIPS G; CHAN KW THALIDOMIDE IN THE MANAGEMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN FOLLOWING BONE-MARROW TRANSPLANTATION | 25 | 30 |
169 | 19 | 42 | 593 1997 CLINICAL NEUROPHARMACOLOGY 20(2):152-164 Zhu J; Bai XF; Mix E; vanderMeide PH; Zwingenberger K; Link H Thalidomide suppresses T-and B-cell responses to myelin antigen in experimental allergic neuritis | 3 | 4 |
170 | 4 | 42 | 785 1999 BRITISH JOURNAL OF CANCER 79(1):114-118 Verheul HMW; Panigrahy D; Yuan J; D'Amato RJ Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits | 17 | 33 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
171 | 20 | 42 | 786 1999 BRITISH JOURNAL OF CANCER 80(5-6):716-723 Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid | 11 | 26 |
172 | 5 | 42 | 1053 2000 SEMINARS IN HEMATOLOGY 37(1):35-39 Alexanian R; Anderson KC; Barlogie B; Stirling DI; Thomas DA Thalidomide in hematologic malignancies: Future directions | 5 | 5 |
173 | 29 | 42 | 1242 2001 LUPUS 10(3):188-192 Karim MY; Ruiz-Irastorza G; Khamashta MA; Hughes GRV Update on therapy - thalidomide in the treatment of lupus | 6 | 13 |
174 | 17 | 42 | 1308 2002 BIOMEDICINE & PHARMACOTHERAPY 56(1):13-19 Sampaio EP; Hernandez MO; Carvalho DS; Sarno EN Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M-leprae-induced TNF alpha production in vitro | 5 | 6 |
175 | 23 | 42 | 1495 2002 JOURNAL OF IMMUNOLOGY 168(10):4914-4919 Dredge K; Marriott JB; Todryk SM; Muller GW; Chen R; Stirling DI; Dalgleish AG Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity | 14 | 29 |
176 | 18 | 42 | 1604 2003 BLOOD 102(1):69-77 Mileshkin L; Biagi JJ; Mitchell P; Underhill C; Grigg A; Bell R; McKendrick J; Briggs P; Seymour JF; Lillie K; Smith JG; Zeldis JB; Prince HM Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age | 7 | 10 |
177 | 6 | 42 | 1712 2003 DIABETOLOGIA 46(12):1669-1675 Bosco AA; Lerario AC; Santos RF; Wajchenberg BL Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats | 1 | 1 |
178 | 16 | 42 | 1730 2003 INTERNATIONAL IMMUNOPHARMACOLOGY 3(10-11):1447-1456 Karrow NA; Guo TL; Zhang LX; McCay JA; Musgrove DL; Peachee VL; Germolec DR; White KL Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study | 0 | 1 |
179 | 9 | 42 | 1751 2003 JOURNAL OF INTERFERON AND CYTOKINE RESEARCH 23(1):3-10 Bauer JA; Morrison BH; Grane RW; Jacobs BS; Borden EC; Lindner DJ IFN-alpha 2b and thalidomide synergistically inhibit tumor-induced angiogenesis | 0 | 2 |
180 | 9 | 42 | 1921 2004 JOURNAL OF CLINICAL ONCOLOGY 22(13):2532-2539 Dahut WL; Gulley JL; Arlen PM; Liu Y; Fedenko KM; Steinberg SM; Wright JJ; Parnes H; Chen CC; Jones E; Parker CE; Linehan WM; Figg WD Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
181 | 24 | 42 | 1925 2004 JOURNAL OF IMMUNOLOGY 172(8):5103-5109 Gockel HR; Lugering A; Heidemann J; Schmidt M; Domschke W; Kucharzik T; Lugering N Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway | 0 | 0 |
182 | 21 | 42 | 1956 2004 MAYO CLINIC PROCEEDINGS 79(7):883-889 Mesa RA; Elliott MA; Schroeder G; Tefferi A Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia | 1 | 1 |
183 | 6 | 41 | 193 1986 MUSCLE & NERVE 9(9):837-844 LAGUENY A; ROMMEL A; VIGNOLLY B; TAIEB A; VENDEAUDBUSQUET M; DOUTRE MS; JULIEN J THALIDOMIDE NEUROPATHY - AN ELECTROPHYSIOLOGIC STUDY | 21 | 28 |
184 | 17 | 41 | 348 1993 ARCHIVES OF DERMATOLOGY 129(10):1261-1264 THOMAS L; DUCROS B; SECCHI T; BALME B; MOULIN G SUCCESSFUL TREATMENT OF ADULTS LANGERHANS CELL HISTIOCYTOSIS WITH THALIDOMIDE - REPORT OF 2 CASES AND LITERATURE-REVIEW | 23 | 40 |
185 | 11 | 41 | 600 1997 EXPERIMENTAL EYE RESEARCH 64(6):971-978 Kenyon BM; Browne F; DAmato RJ Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization | 97 | 150 |
186 | 11 | 41 | 686 1998 CHEMICAL RESEARCH IN TOXICOLOGY 11(12):1521-1528 Reist M; Carrupt PA; Francotte E; Testa B Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites | 15 | 17 |
187 | 9 | 41 | 710 1998 JOURNAL OF INFECTIOUS DISEASES 177(6):1563-1572 Tsenova L; Sokol K; Freedman VH; Kaplan G Combination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death | 14 | 26 |
188 | 13 | 41 | 1002 2000 JOURNAL OF CHROMATOGRAPHY A 876(1-2):157-167 Meyring M; Chankvetadze B; Blaschke G Simultaneous separation and enantioseparation of thalidomide and its hydroxylated metabolites using high-performance liquid chromatography in common-size columns, capillary liquid chromatography and nonaqueous capillary electrochromatography | 3 | 32 |
189 | 12 | 41 | 1013 2000 JOURNAL OF MEDICAL PRIMATOLOGY 29(1):1-10 Di Fabio S; Trabattoni D; Geraci A; Ruzzante S; Panzini G; Fusi ML; Chiarotti F; Corrias F; Belli R; Verani P; Dalgleish A; Clerici M; Titti F Study of immunological and virological parameters during thalidomide treatment of SIV-infected cynomolgus monkeys | 1 | 1 |
190 | 9 | 41 | 1057 2000 TERATOLOGY 61(3):189-195 Stephens TD; Fillmore BJ Hypothesis: Thalidomide embryopathy - Proposed mechanism of action | 17 | 30 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
191 | 13 | 41 | 1091 2001 BIOORGANIC & MEDICINAL CHEMISTRY 9(5):1279-1291 Hess S; Akermann MA; Wnendt S; Zwingerberger K; Eger K Synthesis and immunological activity of water-soluble thalidomide prodrugs | 2 | 4 |
192 | 11 | 41 | 1266 2001 RHEUMATOLOGY 40(8):933-938 Kari JA; Shah V; Dillon MJ Behcet's disease in UK children: clinical features and treatment including thalidomide | 5 | 16 |
193 | 5 | 41 | 1734 2003 INTERNATIONAL JOURNAL OF ONCOLOGY 22(1):165-173 Yata K; Otsuki T; Kurebayashi J; Uno M; Fujii T; Yawata Y; Takata A; Hyodoh F; Sugihara T Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells | 2 | 3 |
194 | 12 | 41 | 1869 2004 BRITISH JOURNAL OF DERMATOLOGY 151(2):458-464 Cummins DL; Gaspari AA Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus: discordant effects on minimal erythema dose and sunburn cell formation | 0 | 0 |
195 | 10 | 41 | 1918 2004 JOURNAL OF BIOMEDICAL SCIENCE 11(5):591-598 Chen CS; Perng WC; Chen CW; Huang KL; Wu CP; Yen MH Thalidomide reduces lipopolysaccharide/zymosan-induced acute lung injury in rats | 0 | 0 |
196 | 1 | 41 | 1952 2004 LEUKEMIA RESEARCH 28(8):791-803 Raza A; Buonamici S; Lisak L; Tahir S; Li DL; Imran M; Chaudary NI; Pervaiz H; Gallegos JA; Alvi MI; Mumtaz M; Gezer S; Venugopal P; Reddy P; Galili N; Candoni A; Singer J; Nucifora G Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression | 0 | 0 |
197 | 10 | 41 | 1971 2004 PATHOLOGY INTERNATIONAL 54(5):285-294 Du WL; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment | 0 | 0 |
198 | 0 | 40 | 33 1981 TERATOLOGY 23(3):351-364 NEWMAN LM; HENDRICKX AG FETAL EAR MALFORMATIONS INDUCED BY MATERNAL INGESTION OF THALIDOMIDE IN THE BONNET MONKEY (MACACA, RADIATA) | 2 | 13 |
199 | 2 | 40 | 282 1990 JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY 49(6):564-581 DEIONGH RU A QUANTITATIVE ULTRASTRUCTURAL-STUDY OF MOTOR AND SENSORY LUMBOSACRAL NERVE ROOTS IN THE THALIDOMIDE-TREATED RABBIT FETUS | 3 | 3 |
200 | 6 | 40 | 462 1995 HAUTARZT 46(8):553-560 DALLAFIOR S; PUGIN P; CERNY T; BETTICHER D; SAURAT JH; HAUSER C A CASE OF CUTANEOUS LANGERHANS CELL GRANULOMATOSIS SUCCESSFULLY TREATED WITH 2-CHLORODEOXYADENOSINE AND THALIDOMIDE | 4 | 9 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
201 | 16 | 40 | 808 1999 GASTROENTEROLOGY 117(6):1278-1287 Vasiliauskas EA; Kam LY; Abreu-Martin MT; Hassard PV; Papadakis KA; Yang HY; Zeldis JB; Targan SR An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease | 43 | 129 |
202 | 8 | 40 | 862 1999 REPRODUCTIVE TOXICOLOGY 13(6):547-554 Hansen JM; Carney EW; Harris C Differential alteration by thalidomide of the glutathione content of rat vs. rabbit conceptuses in vitro | 6 | 11 |
203 | 13 | 40 | 867 1999 SURGERY 125(5):536-544 Kotoh T; Dhar DK; Masunaga R; Tabara H; Tachibana M; Kubota H; Kohno H; Nagasue N Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice | 12 | 27 |
204 | 19 | 40 | 987 2000 HUMAN & EXPERIMENTAL TOXICOLOGY 19(11):615-622 Teo S; Evans M; Ehrhart J; Brockman M; Allen D; Morgan M; Stirling D; Thomas S Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules | 0 | 0 |
205 | 21 | 40 | 1005 2000 JOURNAL OF CLINICAL ONCOLOGY 18(14):2710-2717 Baidas SM; Winer EP; Fleming GF; Harris L; Pluda JM; Crawford JG; Yamauchi H; Isaacs C; Hanfelt J; Tefft M; Flockhart D; Johnson MD; Hawkins MJ; Lippman ME; Hayes DF Phase II evaluation of thalidomide in patients with metastatic breast cancer | 39 | 54 |
206 | 7 | 40 | 1259 2001 OPHTHALMOLOGICA 215(4):284-289 Kaven C; Spraul CW; Zavazava N; Lang GK; Lang GE Thalidomide and prednisolone inhibit growth factor-induced human retinal pigment epithelium cell proliferation in vitro | 2 | 7 |
207 | 8 | 40 | 1269 2001 SEMINARS IN ONCOLOGY 28(4):62-66 Figg WD; Arlen P; Gulley J; Fernandez P; Noone M; Fedenko K; Hamilton M; Parker C; Kruger EA; Pluda J; Dahut WL A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer | 16 | 38 |
208 | 13 | 40 | 1291 2002 ANALYTICAL CHEMISTRY 74(15):3726-3735 Meyring M; Muhlbacher J; Messer K; Kastner-Pustet N; Bringmann G; Mannschreck A; Blaschke G In vitro biotransformation of (R)- and (S)-thalidomide: Application of circular dichroism spectroscopy to the stereochemical characterization of the hydroxylated metabolites | 0 | 3 |
209 | 4 | 40 | 1477 2002 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 8(5):256-259 Barthel HR; Charrier U; Kramer M; Loch C Successful treatment of idiopathic febrile panniculitis (Weber-Christian disease) with thalidomide in a patient having failed multiple other medical therapies | 0 | 0 |
210 | 4 | 40 | 1505 2002 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 27(3-4):497-505 Trapp O; Schoetz G; Schurig V Stereointegrity of thalidomide: gas-chromatographic determination of the enantiomerization barrier | 0 | 2 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
211 | 10 | 40 | 1507 2002 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 300(3):768-776 Hansen JM; Harris KK; Philbert MA; Harris C Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb | 2 | 5 |
212 | 19 | 40 | 1682 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(4):607-616 Kropff MH; Lang N; Bisping G; Domine N; Innig G; Hentrich M; Mitterer M; Sudhoff T; Fenk R; Straka C; Heinecke A; Koch OM; Ostermann H; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma | 5 | 9 |
213 | 6 | 40 | 1732 2003 INTERNATIONAL JOURNAL OF HEMATOLOGY 78(5):443-449 Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Nevruz O; Sengul A; Yalcin A The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide | 0 | 2 |
214 | 19 | 40 | 1750 2003 JOURNAL OF INFECTIOUS DISEASES 187(6):946-955 Haslett PAJ; Hanekom WA; Muller G; Kaplan G Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8(+) T cells in vitro | 0 | 0 |
215 | 32 | 40 | 1867 2004 BRITISH JOURNAL OF CANCER 90(5):955-961 Bartlett JB; Michael A; Clarke IA; Dredge K; Nicholson S; Kristeleit H; Polychronis A; Pandha H; Muller GW; Stirling DI; Zeldis J; Dalgleish AG Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers | 1 | 1 |
216 | 11 | 40 | 1945 2004 LEUKEMIA 18(3):624-627 Kumar S; Witzig TE; Dispenzieri A; Lacy MQ; Wellik LE; Fonseca R; Lust JA; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma | 1 | 1 |
217 | 0 | 39 | 9 1981 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 31-1(6):941-949 HELM FC; FRANKUS E; FRIDERICHS E; GRAUDUMS I; FLOHE L COMPARATIVE TERATOLOGICAL INVESTIGATION OF COMPOUNDS STRUCTURALLY AND PHARMACOLOGICALLY RELATED TO THALIDOMIDE | 0 | 54 |
218 | 0 | 39 | 44 1982 DERMATOLOGICA 165(4):355-362 SCOLARI F; HARMS M; GILARDI S THALIDOMIDE IN THE TREATMENT OF CHRONIC LUPUS-ERYTHEMATOSUS | 7 | 9 |
219 | 8 | 39 | 119 1984 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 11(5):814-819 BARNHILL RL; DOLL NJ; MILLIKAN LE; HASTINGS RC STUDIES ON THE ANTI-INFLAMMATORY PROPERTIES OF THALIDOMIDE - EFFECTS ON POLYMORPHONUCLEAR LEUKOCYTES AND MONOCYTES | 44 | 50 |
220 | 13 | 39 | 262 1989 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 20(6):1060-1063 GRINSPAN D; BLANCO GF; AGUERO S TREATMENT OF APHTHAE WITH THALIDOMIDE | 9 | 24 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
221 | 19 | 39 | 270 1990 BIOMEDICINE & PHARMACOTHERAPY 44(4):199-204 HENEY D; BAILEY CC; LEWIS IJ THALIDOMIDE IN THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 12 | 14 |
222 | 11 | 39 | 522 1996 DEVELOPMENT GROWTH & DIFFERENTIATION 38(1):47-57 Audit CO; Eger K; Aimar C Possible involvement of an acylation mechanism in thalidomide-induced teratogenesis of the newt (Pleurodeles waltl) | 2 | 2 |
223 | 11 | 39 | 602 1997 GASTROENTEROLOGY 112(6):1823-1829 Sharpstone D; Rowbottom A; Francis N; Tovey G; Ellis D; Barrett M; Gazzard B Thalidomide: A novel therapy for microsporidiosis | 12 | 42 |
224 | 12 | 39 | 746 1999 AIDS RESEARCH AND HUMAN RETROVIRUSES 15(13):1169-1179 Haslett PAJ; Klausner JD; Makonkawkeyoon S; Moreira A; Metatratip P; Boyle B; Kunachiwa W; Maneekarn N; Vongchan P; Corral LG; Elbeik T; Shen Z; Kaplan G Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients | 27 | 33 |
225 | 16 | 39 | 855 1999 ORGANIC LETTERS 1(10):1571-1573 Takeuchi Y; Shiragami T; Kimura K; Suzuki E; Shibata N (R)- and (S)-3-fluorothalidomides: Isosteric analogues of thalidomide | 3 | 14 |
226 | 24 | 39 | 1389 2002 BLOOD 100(12):4162-4168 Yaccoby S; Johnson CL; Mahaffey SC; Wezeman MJ; Barlogie B; Epstein J Antimyeloma efficacy of thalidomide in the SCID-hu model | 1 | 6 |
227 | 4 | 39 | 1694 2003 CELLULAR AND MOLECULAR BIOLOGY 49(7):1117-1124 Ezell TN; Maloney N; Githua JW; Taylor LD Exposure to the anti-TNF-alpha drug thalidomide induces apoptotic cell death in human T leukemic cells | 0 | 0 |
228 | 11 | 39 | 1731 2003 INTERNATIONAL JOURNAL OF DERMATOLOGY 42(5):372-375 Alfadley A; Al-Hawsawi K; Thestrup-Pedersen K; Al-Aboud K Treatment of prurigo nodularis with thalidomide: a case report and review of the literature | 0 | 0 |
229 | 9 | 39 | 1760 2003 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 305(3):1222-1232 Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PPM; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs | 3 | 4 |
230 | 23 | 39 | 1796 2003 MAYO CLINIC PROCEEDINGS 78(1):34-39 Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma | 9 | 21 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
231 | 4 | 38 | 96 1983 SEMAINE DES HOPITAUX 59(45):3101-3104 BELAUBE P; GARCIN G; MARCHAND JP; PRIVAT Y SHOULD THALIDOMIDE BE REHABILITATED | 4 | 7 |
232 | 1 | 38 | 173 1985 TERATOLOGY 32(1):133-144 NEWMAN CGH TERATOGEN UPDATE - CLINICAL ASPECTS OF THALIDOMIDE EMBRYOPATHY - A CONTINUING PREOCCUPATION | 9 | 28 |
233 | 0 | 38 | 208 1987 EUROPEAN JOURNAL OF PEDIATRICS 146(1):63-67 SCHAFER KH; KRAMER M INFANTILE HYPERTROPHIC PYLORIC-STENOSIS AFTER PRENATAL EXPOSURE TO THALIDOMIDE | 0 | 0 |
234 | 11 | 38 | 287 1990 LEUKEMIA RESEARCH 14(5):395-399 WOOD PMD; PROCTOR SJ THE POTENTIAL USE OF THALIDOMIDE IN THE THERAPY OF GRAFT-VERSUS-HOST DISEASE - A REVIEW OF CLINICAL AND LABORATORY INFORMATION | 17 | 26 |
235 | 6 | 38 | 293 1990 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 10(4):281-294 HUANG PHT; MCBRIDE WG THALIDOMIDE INDUCED ALTERATION IN SECONDARY STRUCTURE OF RAT EMBRYONIC DNA INVIVO | 6 | 12 |
236 | 28 | 38 | 354 1993 BONE MARROW TRANSPLANTATION 12:S26-S28 EHNINGER G; EGER K; STUHLER A; SCHULER U THALIDOMIDE - THE NEED FOR A NEW CLINICAL-EVALUATION OF AN OLD DRUG | 7 | 8 |
237 | 23 | 38 | 450 1995 CLINICAL INFECTIOUS DISEASES 20(2):250-254 PATERSON DL; GEORGHIOU PR; ALLWORTH AM; KEMP RJ THALIDOMIDE AS TREATMENT OF REFRACTORY APHTHOUS ULCERATION RELATED TO HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION | 38 | 60 |
238 | 14 | 38 | 474 1995 LIFE SCIENCES 58(4):295-316 Neubert R; Hinz N; Thiel R; Neubert D Down-regulation of adhesion receptors on cells of primate embryos as a probable mechanism of the teratogenic action of thalidomide | 3 | 7 |
239 | 5 | 38 | 490 1996 AIDS 10(13):1501-1507 ReyesTeran G; SierraMadero JG; delCerro VM; ArroyoFigueroa H; Pasquetti A; Calva JJ; RuizPalacios GM Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial | 49 | 98 |
240 | 19 | 38 | 886 2000 ANTI-CANCER DRUGS 11(10):787-791 Adlard JW Thalidomide in the treatment of cancer | 5 | 11 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
241 | 11 | 38 | 945 2000 BRITISH JOURNAL OF CANCER 82(4):812-817 Eisen T; Boshoff C; Mak I; Sapunar F; Vaughan MM; Pyle L; Johnston SRD; Ahern R; Smith IE; Gore ME Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer | 78 | 130 |
242 | 8 | 38 | 1043 2000 PAIN 88(3):267-275 George A; Marziniak M; Schafers M; Toyka KV; Sommer C Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin | 4 | 21 |
243 | 10 | 38 | 1145 2001 BONE MARROW TRANSPLANTATION 28(12):1145-1150 Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation | 3 | 5 |
244 | 8 | 38 | 1159 2001 BRITISH JOURNAL OF PHARMACOLOGY 133(8):1414-1423 Lienenluke B; Stojanovic T; Fiebig T; Fayyazi A; Germann T; Hecker M Thalidomide impairment of trinitrobenzene sulphonic acid-induced colitis in the rat-role of endothelial cell-leukocyte interaction | 3 | 4 |
245 | 6 | 38 | 1437 2002 DEVELOPMENTAL DYNAMICS 225(2):186-194 Hansen JM; Gong SG; Philbert M; Harris C Misregulation of gene expression in the redox-sensitive NF-kappa B-dependent limb outgrowth pathway by thalidomide | 1 | 3 |
246 | 12 | 38 | 1456 2002 GASTROENTEROLOGY 123(1):291-300 Enomoto N; Takei Y; Hirose M; Ikejima K; Miwa H; Kitamura T; Sato N Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-alpha production | 3 | 14 |
247 | 11 | 38 | 1518 2002 LEUKEMIA 16(9):1609-1614 Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study | 8 | 13 |
248 | 17 | 38 | 1526 2002 LUPUS 11(2):67-70 Piette JC; Sbai A; Frances C Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus | 3 | 5 |
249 | 4 | 38 | 1532 2002 MICROBES AND INFECTION 4(11):1193-1202 Teo SK; Resztak KE; Scheffler MA; Kook KA; Zeldis JB; Stirling DI; Thomas SD Thalidomide in the treatment of leprosy | 8 | 10 |
250 | 26 | 38 | 1698 2003 CLINICAL CANCER RESEARCH 9(5):1680-1688 Lu J; Palmer BD; Kestell P; Browett P; Baguley BC; Muller G; Ching LM Thalidomide metabolites in mice and patients with multiple myeloma | 7 | 8 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
251 | 13 | 38 | 1708 2003 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S59-S65 Amato RJ Thalidomide therapy for renal cell carcinoma | 0 | 1 |
252 | 26 | 38 | 1790 2003 LEUKEMIA & LYMPHOMA 44(7):1141-1146 Flowers MED; Martin PJ Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease | 0 | 0 |
253 | 3 | 38 | 1866 2004 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 37(4):485-492 Arruda MSP; Richini VB; Oliveira SMA; Vilani-Moreno FR Experimental murine mycobacteriosis: evaluation of the functional activity of alveolar macrophages in thalidomide-treated mice | 0 | 0 |
254 | 0 | 37 | 93 1983 PERSPECTIVES IN BIOLOGY AND MEDICINE 27(1):93-106 WYATT HV DID THALIDOMIDE PROMOTE POLIOMYELITIS FOLLOWING ORAL POLIOVIRUS VACCINATION IN WEST-BERLIN IN 1960 | 0 | 4 |
255 | 4 | 37 | 344 1992 ZEITSCHRIFT FUR NATURFORSCHUNG C-A JOURNAL OF BIOSCIENCES 47(1-2):155-169 KOCHERBECKER U; KOCHER W; OCKENFELS H EMBRYOTOXIC INTERACTIONS BETWEEN A HYDROLYSIS PRODUCT OF THALIDOMIDE AND THE SURFACTANT TWEEN 20 IN MICE | 0 | 0 |
256 | 19 | 37 | 708 1998 JOURNAL OF EXPERIMENTAL MEDICINE 187(11):1885-1892 Haslett PAJ; Corral LG; Albert M; Kaplan G Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset | 144 | 179 |
257 | 9 | 37 | 852 1999 NEW ENGLAND JOURNAL OF MEDICINE 341(21):1565-1571 Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeldis J; Barlogie B; Siegel D; Crowley J Antitumor activity of thalidomide in refractory multiple myeloma. | 293 | 558 |
258 | 3 | 37 | 1055 2000 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 20(1):35-47 Fort DJ; Stover EL; Bantle JA; Finch RA Evaluation of the developmental toxicity of thalidomide using Frog Embryo Teratogenesis Assay-Xenopus (FETAX): Biotransformation and detoxification | 6 | 8 |
259 | 18 | 37 | 1061 2000 TOXICOLOGY AND APPLIED PHARMACOLOGY 165(3):237-244 Karrow NA; McCay JA; Brown RD; Musgrove DL; Pettit DA; Munson AE; Germolec DR; White KL Thalidomide stimulates splenic IgM antibody response and cytotoxic T lymphocyte activity and alters leukocyte subpopulation numbers in female B6C3F1 mice | 5 | 8 |
260 | 16 | 37 | 1147 2001 BRITISH JOURNAL OF CANCER 85(7):953-958 Stebbing J; Benson C; Eisen T; Pyle L; Smalley K; Bridle H; Mak I; Sapunar F; Ahern R; Gore ME The treatment of advanced renal cell cancer with high-dose oral thalidomide | 19 | 31 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
261 | 7 | 37 | 1161 2001 CANCER CHEMOTHERAPY AND PHARMACOLOGY 47(4):319-326 Zhou S; Paxton JW; Kestell P; Tingle MD; Ching LM In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac | 2 | 10 |
262 | 33 | 37 | 1421 2002 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 130(1):75-84 Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells | 17 | 19 |
263 | 21 | 37 | 1490 2002 JOURNAL OF CLINICAL ONCOLOGY 20(21):4319-4323 Rajkumar SV; Hayman S; Gertz MA; Dispenzieri A; Lacy MQ; Greipp PR; Geyer S; Iturria N; Fonseca R; Lust JA; Kyle RA; Witzig TE Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma | 33 | 57 |
264 | 3 | 37 | 1565 2003 AMERICAN JOURNAL OF HEMATOLOGY 73(1):48-53 Lee FC; Merchant SH Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide | 1 | 4 |
265 | 27 | 37 | 1576 2003 ANNALS OF HEMATOLOGY 82(9):558-564 Huang SY; Tang JL; Yao M; Ko BS; Hong RL; Tsai W; Wang CH; Tien HF; Shen MC; Chen YC Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma | 0 | 0 |
266 | 16 | 37 | 1713 2003 DRUG METABOLISM AND DISPOSITION 31(4):469-475 Miyata M; Tamura E; Motoki K; Nagata K; Yamazoe Y Thalidomide-induced suppression of embryo fibroblast proliferation requires CYP1A1-mediated activation | 2 | 2 |
267 | 4 | 37 | 1742 2003 JOURNAL OF CLINICAL ONCOLOGY 21(12):2299-2304 Fine HA; Wen PY; Maher EA; Viscosi E; Batchelor T; Lakhani N; Figg WD; Purow BW; Borkowf CB Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas | 2 | 5 |
268 | 5 | 37 | 1743 2003 JOURNAL OF CLINICAL ONCOLOGY 21(13):2551-2557 Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma | 2 | 7 |
269 | 10 | 37 | 1813 2003 PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE 19(6):272-280 Lu KQ; Brenneman S; Burns R; Vink A; Gaines E; Haake A; Gaspari A Thalidomide inhibits UVB-induced mouse keratinocyte apoptosis by both TNF-alpha-dependent and TNF-alpha-independent pathways | 0 | 0 |
270 | 0 | 37 | 1900 2004 EXPERIMENTAL BRAIN RESEARCH 156(3):333-341 Stoeckel MC; Pollok B; Schnitzler A; Witte OW; Seitz RJ Use-dependent cortical plasticity in thalidomide-induced upper extremity dysplasia: evidence from somaesthesia and neuroimaging | 0 | 0 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
271 | 19 | 37 | 1909 2004 HAEMATOLOGICA 89(7):826-831 Cavo M; Zamagni E; Tosi P; Cellini C; Cangini D; Tacchetti P; Testoni N; Tonelli M; De Vivo A; Palareti G; Tura S; Baccarani M First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma | 0 | 0 |
272 | 0 | 36 | 8 1981 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 31-1(2):315-320 FLOHE L; DRAEGER E; FRANKUS E; GRAUDUMS I; GUNZLER WA; HELM FC; KUUTTISAVOLAINEN ER STUDIES ON THE HYPOTHETICAL RELATIONSHIP OF THALIDOMIDE-INDUCED EMBRYOPATHY AND COLLAGEN BIOSYNTHESIS | 0 | 10 |
273 | 0 | 36 | 29 1981 SCANDINAVIAN JOURNAL OF IMMUNOLOGY 13(6):553-562 SHANNON EJ; MIRANDA RO; MORALES MJ; HASTINGS RC INHIBITION OF DENOVO IGM ANTIBODY-SYNTHESIS BY THALIDOMIDE AS A RELEVANT MECHANISM OF ACTION IN LEPROSY | 32 | 41 |
274 | 1 | 36 | 90 1983 MEDICAL HYPOTHESES 10(4):437-443 HENDLER SS; MCCARTY MF THALIDOMIDE FOR AUTOIMMUNE-DISEASE | 13 | 14 |
275 | 2 | 36 | 178 1986 ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH 36-2(7):1138-1141 GUNZLER V; HANAUSKEABEL HM; TSCHANK G; SCHULTEWISSERMANN H IMMUNOLOGICAL EFFECTS OF THALIDOMIDE - INACTIVITY OF THE DRUG AND SEVERAL OF ITS HYDROLYSIS PRODUCTS IN MONONUCLEOCYTE PROLIFERATION TESTS | 0 | 10 |
276 | 6 | 36 | 518 1996 CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY 81(3):219-223 Klausner JD; Freedman VH; Kaplan G Thalidomide as an anti-TNF-alpha inhibitor: Implications for clinical use | 40 | 57 |
277 | 19 | 36 | 802 1999 ETHIOPIAN MEDICAL JOURNAL 37(4):275-280 Shannon EJ 24th Kellersberger Memorial Lecture, 1999 thalidomide: Will the past overshadow a promising future? | 0 | 0 |
278 | 27 | 36 | 1014 2000 JOURNAL OF PHARMACY AND PHARMACOLOGY 52(7):807-817 Eriksson T; Bjorkman S; Roth B; Hoglund P Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man | 10 | 17 |
279 | 18 | 36 | 1212 2001 INFLAMMATION 25(2):91-96 Belo AV; Ferreira MAND; Bosco AA; Machado RDP; Andrade SP Differential effects of thalidomide on angiogenesis and tumor growth in mice | 0 | 2 |
280 | 21 | 36 | 1283 2002 ALIMENTARY PHARMACOLOGY & THERAPEUTICS 16(6):1117-1124 Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease | 4 | 15 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
281 | 9 | 36 | 1299 2002 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 46(6):1887-1895 Tsenova L; Mangaliso B; Muller G; Chen Y; Freedman VH; Stirling D; Kaplan G Use of IMiD3, a thalidomide analog, as an adjunct to therapy for experimental tuberculous meningitis | 3 | 5 |
282 | 18 | 36 | 1317 2002 BLOOD 99(3):834-839 Steins MB; Padro T; Bieker R; Ruiz S; Kropff M; Kienast J; Kessler T; Buechner T; Berdel WE; Mesters RM Efficacy and safety of thalidomide in patients with acute myeloid leukemia | 11 | 25 |
283 | 10 | 36 | 1398 2002 BRITISH JOURNAL OF CANCER 87(10):1166-1172 Dredge K; Marriott JB; Macdonald CD; Man HW; Chen R; Muller GW; Stirling D; Dalgleish AG Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects | 10 | 16 |
284 | 12 | 36 | 1400 2002 BRITISH JOURNAL OF HAEMATOLOGY 117(2):288-296 Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A Thalidomide treatment in myelofibrosis with myeloid metaplasia | 13 | 23 |
285 | 19 | 36 | 1445 2002 EUROPEAN JOURNAL OF PHARMACOLOGY 453(2-3):325-334 Thiele A; Bang R; Gutschow M; Rossol M; Loos S; Eger K; Tiegs G; Hauschildt S Cytokine modulation and suppression of liver injury by a novel analogue of thalidomide | 1 | 3 |
286 | 13 | 36 | 1458 2002 GUT 50(2):196-200 Bauditz J; Wedel S; Lochs H Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease | 11 | 25 |
287 | 13 | 36 | 1746 2003 JOURNAL OF CLINICAL ONCOLOGY 21(20):3770-3776 Hernberg M; Virkkunen P; Bono P; Atinen H; Maenpaa H; Joensuu H Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma | 2 | 4 |
288 | 19 | 36 | 1792 2003 LEUKEMIA & LYMPHOMA 44(9):1489-1493 Steins MB; Bieker R; Padro T; Kessler T; Kienast J; Berdel WE; Mesters RM Thalidomide for the treatment of acute myeloid leukemia | 0 | 0 |
289 | 11 | 36 | 1848 2004 ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 24(5):885-891 Park SJ; Kim HS; Yang HM; Park KW; Youn SW; Jeon SI; Kim DH; Koo BK; Chae IH; Choi DJ; Oh BH; Lee MM; Park YB Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery | 0 | 0 |
290 | 3 | 35 | 107 1984 ARCHIVES OF DERMATOLOGY 120(11):1466-1470 ARONSON IK; YU R; WEST DP; VANDENBROEK H; ANTEL J THALIDOMIDE-INDUCED PERIPHERAL NEUROPATHY - EFFECT OF SERUM FACTOR ON NERVE CULTURES | 35 | 39 |
# | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
291 | 1 | 35 | 182 1986 CLINICS IN PERINATOLOGY 13(3):555-573 NEWMAN CGH THE THALIDOMIDE SYNDROME - RISKS OF EXPOSURE AND SPECTRUM OF MALFORMATIONS | 6 | 19 |
292 | 11 | 35 | 370 1993 MOLECULAR AND CELLULAR BIOCHEMISTRY 129(2):195-200 WEGLICKI WB; STAFFORD RE; DICKENS BF; MAK IT; CASSIDY MM; PHILLIPS TM INHIBITION OF TUMOR-NECROSIS-FACTOR-ALPHA BY THALIDOMIDE IN MAGNESIUM-DEFICIENCY | 4 | 9 |
293 | 6 | 35 | 582 1997 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 30(10):1199-1207 Moreira AL; Wang J; Sarno EN; Kaplan G Thalidomide protects mice against LPS-induced shock | 11 | 13 |
294 | 5 | 35 | 605 1997 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 19(3):313-326 Aseffa A; Dietrich MA; Shannon EJ Effect of thalidomide on apoptosis of lymphocytes and neutrophils | 4 | 5 |
295 | 22 | 35 | 787 1999 CANCER CHEMOTHERAPY AND PHARMACOLOGY 43:S78-S84 Dixon SC; Kruger EA; Bauer KS; Figg WD Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells | 8 | 14 |
296 | 13 | 35 | 864 1999 SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 12(6):305-311 Monastirli A; Georgiou S; Bolsen K; Pasmatzi E; Papapanagiotou A; Goerz G; Kalofoutis A; Merk HF; Tsambaos D Treatment of porphyria cutanea tarda with oral thalidomide | 5 | 7 |
297 | 7 | 35 | 1052 2000 SEMINARS IN HEMATOLOGY 37(1):26-34 Thomas DA Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders | 9 | 13 |
298 | 12 | 35 | 1171 2001 CLINICAL CANCER RESEARCH 7(9):2675-2681 Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma | 15 | 29 |
299 | 12 | 35 | 1321 2002 BLOOD 99(12):4525-4530 Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Richardson PG; Hideshima T; Munshi NC; Treon SP; Anderson KC Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications | 14 | 54 |
300 | 15 | 35 | 1463 2002 HAEMATOLOGICA 87(4):408-414 Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma | 19 | 29 |